A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with docetaxel at inception of primary hormone therapy
Latest Information Update: 28 Jul 2020
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CANTATA
- 04 Sep 2015 Accrual to date is 10% according to the United Kingdom Clinical Research Network record.
- 12 Aug 2015 Accrual to date is 9% according to United Kingdom Clinical Research Network record.
- 02 Jul 2015 Accrual to date is 8% according to United Kingdom Clinical Research Network record.